https://www.selleckchem.com/pr....oducts/6-aminonicoti
1. A total of 127 patients were randomized to CZP 400mg Q2W (N = 53), CZP 200mg Q2W (N = 48), placebo (N = 26). Week16 responder rates for CZP 400mg/200mg Q2W versus placebo were 87.1%/73.0% versus 7.9% for PASI75; 75.7%/53.8% versus 0.2% for PASI90; 66.7%/52.7% versus 0.0% for PGA0/1 (all p 0.0001 for both CZP doses versus placebo). Significant improvements in DLQI and INRS were reported at week16 by patients receiving both CZP doses compared with placebo (p 0.0001). Incidence of treatment-emergent adverse events
Like
Comment
Share
